antirheumatic agents

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A Connell, Zoltan Szekanecz

Annals of the Rheumatic Diseases Jan 2023, 82 (1) 119-129; DOI: 10.1136/ard-2022-222259
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, Benedicte Delcoigne, Daniela Di Giuseppe, Johan Askling

Annals of the Rheumatic Diseases Feb 2023, 82 (2) 189-197; DOI: 10.1136/ard-2022-223050
Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Alvise Berti, Fabiola Atzeni, Lorenzo Dagna, Stefano Del Giacco, Giacomo Emmi, Carlo Salvarani, Augusto Vaglio

Annals of the Rheumatic Diseases Feb 2023, 82 (2) 164-168; DOI: 10.1136/ard-2022-223044
Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?
Ana Lorenzo-Vizcaya, David Alan Isenberg

Annals of the Rheumatic Diseases Feb 2023, 82 (2) 169-174; DOI: 10.1136/ard-2022-222839
Correspondence on ‘Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease’
Jiali Chen, Tian Liu, Jing He, Yudong Liu

Annals of the Rheumatic Diseases Feb 2023, 82 (2) e48; DOI: 10.1136/annrheumdis-2020-219472
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 433-439; DOI: 10.1136/annrheumdis-2021-221461
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
Féline P B Kroon, Aurélie Najm, Alessia Alunno, Jan W Schoones, Robert B M Landewé, Pedro M Machado, Victoria Navarro-Compán

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 422-432; DOI: 10.1136/annrheumdis-2021-221575
When extended genetics rescues diagnosis: a patient with CANDLE-like phenotype and de novo mutation in the SAMD9L gene
Amandine Remy, Charlotte Borocco, Guillaume Sarrabay, Guilaine Boursier, Sylvie Fraitag, Benoit Catteau, Héloise Reumaux, Isabelle Koné-Paut

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 447-448; DOI: 10.1136/annrheumdis-2021-221486
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Robert Spiera, Sarah Jinich, Deanna Jannat-Khah

Annals of the Rheumatic Diseases Oct 2021, 80 (10) 1357-1359; DOI: 10.1136/annrheumdis-2021-220604
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Mirko Scarsi, Silvia Piantoni, Enrico Colombo, Paolo Airó, Donata Richini, Marco Miclini, Valeria Bertasi, Marta Bianchi, Damiano Bottone, Patrizia Civelli, Maria-Sofia Cotelli, Ezio Damiolini, Gloria Galbassini, Diego Gatta, Maria-Laura Ghirardelli, Roberto Magri, Paola Malamani, Monia Mendeni, Stefano Molinari, Andrea Morotti, Luisa Salada, Marinella Turla, Angiola Vender, Angela Tincani, Antonio Brucato, Franco Franceschini, Roberto Furloni, Laura Andreoli

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1286-1289; DOI: 10.1136/annrheumdis-2020-217712

Main menu

antirheumatic agents

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

antirheumatic agents

Pages